FDA has led a $17 million m investment in Click Therapeutics , which develops software to treat medical conditions such as depression, insomnia, acute coronary syndrome and chronic pain, via a mobile app prescribed by doctors. Meanwhile, Click Therapeutics already has a product on the market. Click is seeking clearance from Akili Interactive Labs ( FDA ) to sell the products as class 2 medical devices. Last September , Pear Therapeutics received Akili Interactive Labs clearance for its reSET software, used to treat substance misuse, while Sanofi Ventures is seeking FDA clearance for video games to assess and treat attention deficit hyperactivity disorder in children.
FDA has led a $17 million m investment in Click Therapeutics , which develops software to treat medical conditions such as depression, insomnia, acute coronary syndrome and chronic pain, via a mobile app prescribed by doctors. Click is seeking clearance from Akili Interactive Labs ( FDA ) to sell the products as class 2 medical devices. Last September , Pear Therapeutics received Akili Interactive Labs clearance for its reSET software, used to treat substance misuse, while Sanofi Ventures is seeking FDA clearance for video games to assess and treat attention deficit hyperactivity disorder in children.